- Home
- ASC vs CGEM Comparison
ASC vs CGEM Comparison
Compare ASC & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASC
- CGEM
- Stock Information
- Founded
- ASC 2010
- CGEM 2016
- Country
- ASC Bermuda
- CGEM United States
- Employees
- ASC N/A
- CGEM N/A
- Industry
- ASC Marine Transportation
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- ASC Consumer Discretionary
- CGEM Health Care
- Exchange
- ASC Nasdaq
- CGEM Nasdaq
- Market Cap
- ASC 510.3M
- CGEM 437.2M
- IPO Year
- ASC 2013
- CGEM 2021
- Fundamental
- Price
- ASC $12.21
- CGEM $7.85
- Analyst Decision
- ASC Buy
- CGEM Strong Buy
- Analyst Count
- ASC 3
- CGEM 7
- Target Price
- ASC $12.67
- CGEM $26.00
- AVG Volume (30 Days)
- ASC 473.7K
- CGEM 1.5M
- Earning Date
- ASC 11-05-2025
- CGEM 11-07-2025
- Dividend Yield
- ASC 7.78%
- CGEM N/A
- EPS Growth
- ASC N/A
- CGEM N/A
- EPS
- ASC 1.04
- CGEM N/A
- Revenue
- ASC $324,200,000.00
- CGEM N/A
- Revenue This Year
- ASC N/A
- CGEM N/A
- Revenue Next Year
- ASC $20.24
- CGEM N/A
- P/E Ratio
- ASC $12.10
- CGEM N/A
- Revenue Growth
- ASC N/A
- CGEM N/A
- 52 Week Low
- ASC $8.32
- CGEM $5.68
- 52 Week High
- ASC $15.25
- CGEM $17.50
- Technical
- Relative Strength Index (RSI)
- ASC 56.20
- CGEM 56.01
- Support Level
- ASC $11.50
- CGEM $7.69
- Resistance Level
- ASC $12.65
- CGEM $8.69
- Average True Range (ATR)
- ASC 0.35
- CGEM 0.63
- MACD
- ASC 0.11
- CGEM 0.08
- Stochastic Oscillator
- ASC 76.06
- CGEM 60.17
About ASC Ardmore Shipping Corporation
Ardmore Shipping Corp provides seaborne transportation of petroleum products and chemicals world-wide to oil majors, national oil companies, oil and chemical traders, and chemical companies, with its modern, fuel-efficient fleet of mid-size product and chemical tankers. The Company operates its business in one operating segment, the transportation of refined petroleum products and chemicals.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.